Alpine Immune, Horizon partner to develop protein-based immunotherapies
The collaboration combines Alpine's discovery platform and expertise with Horizon's drug development and commercialisation capabilities
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
17 Dec 21
The collaboration combines Alpine's discovery platform and expertise with Horizon's drug development and commercialisation capabilities
17 Dec 21
The committee advice allows the European Union (EU) member states to decide on the supply and use of…
16 Dec 21
Orencia is a selective costimulation modulator that disrupts the continuous cycle of T-cell activation and was approved for…
16 Dec 21
The new facility would create more than 50 new jobs in the coming years, in addition to around…
15 Dec 21
The acquisition is expected to expand CSL’s offering across a portfolio focused on renal disease, and iron deficiency…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
15 Dec 21
The investment is expected to expand Novo Nordisk’s production capacity from active pharmaceutical ingredients (API) to assembly and…
14 Dec 21
Arena is a clinical-stage pharmaceutical company involved in the development of potential therapies for the treatment of several…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
14 Dec 21
The partnership will jointly develop and commercialise Foghorn's selective BRM programme, and three additional discovery programmes
13 Dec 21
Previously approved by the authorities in the UK, Japan and South Korea, Cibinqo is an oral Janus kinase…
13 Dec 21
Lilly will make an upfront payment of up to $50m to Regor, in addition to potential milestone payments…